---
schema_version: "secwatch.filing_event.v1"
accession: "0001851734-23-000037"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:45:18.113978+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vistagen completes Pherin acquisition, reports Q3 net loss $9.8M; PH94B Phase 3 adjusted

## Summary
- Acquired Pherin Pharmaceuticals; eliminated all future royalty obligations on PH94B and PH10; added three new pherine candidates.
- PH94B Phase 3 plan: PALISADE-1 had unexpected results; preparing FDA meeting; considering multiple-administration LSAS study.
- PH10 received FDA Fast Track designation for major depressive disorder; Phase 1 trial underway; Phase 2A AjDA topline results expected Q1 2023.
- Q3 net loss $9.8M vs $10.7M YoY; R&D decreased $0.9M to $6.9M; cash $25.0M at Dec 31, 2022.
- Shares outstanding 219.3M, including ~12.4M shares issued for Pherin acquisition.

## SEC filing metadata
- accession: 0001851734-23-000037
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/0001851734-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/vtgn20230207_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001851734-23-000037
- JSON: https://secwatch.observer/filing/0001851734-23-000037.json
- Plain text: https://secwatch.observer/filing/0001851734-23-000037.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported financial results for fiscal year 2023 third quarter ended December 31, 2022.
  - Period: fiscal year 2023 third quarter ended December 31, 2022
  - Result: reported results
  source text: On February 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 third quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/0001851734-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.